PRODUCT EXPLANATION|Struthers A.D., McFayden R. et al. Non adherence with ACE inhibitor therapy: a comparison of different ways of measuring it with observations on its frequency in heart failure. JACC, 1999, 34, 2072-2077.|Azizi M., Rousseau A., Ezan E. et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996 Feb 1, 97(3), 839-44.|Lenfant M., Wdzieczak-Bakala J., Guittet E. et al. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc. Natl. Acad. Sci. USA. 86: 779–782 (1989)|Bonnet D., Lemoine F. M., Ponvert-Delucq S. et al. Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Serapenide) on the growth of human CD34+ subpopulations in response to growth factors. Blood. 82:3307–3314 (1993)|Rousseau A., Michaud A., Chauvet M.-T. et al. The hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 270:3656–3661 (1995)|Azizi M., Ezan E., Reny J.L. et al. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in human. Hypertension. 1999 Mar, 33(3), 879-86|Azizi M., Ezan E., Nicolet L. et al. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension. 1997 Nov, 30(5),1015-9|Pradelles Ph., Frobert Y., Créminon C., et al. Distribution of a negative regulator of haematopoietic stem cell proliferation (AcSDKP) and thymosin ß4 in mouse tissues. FEBS 10125, 1991, 289(2), 171-175|Pradelles P., Frobert Y., Créminon C., et al. Negative regulator of pluripotent hematopoiectic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Bioch. Bioph. Res. Com., 1990, August 16, 170-3, 986-993|Junot C., Nicolet L., Ezan E. et al. Effect of Angiotensin-Converting Enzyme Inhibition on Plasma, Urine, and Tissue Concentrations of Hemoregulatory Peptide Acetyl-Ser-Asp-Lys-Pro in Rats. JPET 291:982-987,1999|PRODUCT CITATIONS|Zhou D., Wang J., HE L.N. et al.Prolyl oligopeptidase attenuates hepatic stellate cell activation through induction of Smad7 and PPAR‑γ. Experimental and Therapeutic Medicine , 13, 780-786 (2017)|Chan G. C. W., Yiu W.H., Wu H.J. N-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice. Hindawi Publishing Corporation, Mediators of Inflammation, Volume 2015, Article ID 283123|Ntsekhe M. , Matthews K., Wolske J. A Pilot Study of Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) and Galectin-3 Levels in Normal Pericardial Fluid and Tuberculous Pericardial Effusion: Implications for Pathogenesis and Prevention of Pericardial Constriction. Heart. 2012 September ; 98(17): 1326–1328|Srivastava S.P., Shi S., Kanasaki M. et al. Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis. Sci Rep. 2016; 6: 29884|Myohanen TT., Tenorio-Laranga J., Jokinen B. et al. Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner. British Journal of Pharmacology (2011) 163 1666–1678
